Related Experiment Videos
Endothelin: role in hypertension
1MRC Multidisciplinary Research Group on Hypertension, Clinical Research Institute of Montreal, University of Montreal, Quebec, Canada. schiffe@ircm.umontreal.ca
Biological Research
|November 27, 1998
Summary
Endothelin-1 (ET-1) is implicated in hypertension and vascular growth. Endothelin antagonists show promise in reducing blood pressure, vascular hypertrophy, and protecting organs in experimental models and some human hypertension cases.
Area of Science:
- Cardiovascular Physiology and Pathophysiology
- Endocrinology
- Pharmacology
Background:
- Endothelins (ET) are peptides produced by endothelial cells, playing roles in cardiovascular function.
- Endothelin-1 (ET-1) is the primary endothelial ET, implicated in cardiovascular disease.
- ET-1 overexpression is observed in various salt-dependent and other hypertensive models.
Purpose of the Study:
- To investigate the role of ET-1 in experimental and human hypertension.
- To evaluate the therapeutic potential of endothelin antagonists in hypertension.
Main Methods:
- Analysis of ET-1 expression in different rat models of hypertension.
- Administration of ETA/B and ETA-selective antagonists in hypertensive rats.
- Assessment of blood pressure, vascular growth, and organ protection.
- Clinical studies involving normotensive and hypertensive human subjects.
Main Results:
- ET-1 overexpression in vascular walls of specific hypertensive models, correlating with blood pressure elevation and vascular hypertrophy.
- Endothelin antagonists reduced blood pressure and vascular growth in rats.
- Protection from renal injury and stroke observed with endothelin antagonists in rats.
- Endothelin-dependent tone detected in normotensive subjects; bosentan showed antihypertensive effects in mild hypertensives.
- Enhanced ET-1 mRNA expression in hypertensive patients, particularly in blacks with familial hypertension.
Conclusions:
- Endothelin-1 plays a significant role in certain experimental hypertensive models and human hypertension.
- Endothelin antagonists demonstrate potential as disease-modifying agents for hypertension.
- Further clinical trials are needed to confirm the efficacy of endothelin antagonists in blunting vascular growth, endothelial dysfunction, and reducing long-term complications in humans.